Compare SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SP Funds S&P 500 Sharia Industry Exclusions ETF vs Viatris Inc — how do they compare? SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $57.07, while Viatris Inc trades at $17.15 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while SP Funds S&P 500 Sharia Industry Exclusions ETF pays none, and Viatris Inc is trading nearer its 52-week high, SP Funds S&P 500 Sharia Industry Exclusions ETF nearer its low. Which is the better fit depends on your goals.
| SPUS | VTRS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $59.51 | $17.39 |
52-Week Low | $45.32 | $8.74 |
Market Cap | — | $19.79B |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPUS trades at $56.32, down 0.23% on the day, with a neutral technical signal overall. The stock shows bullish moving average alignment but oscillators indicate indecision. Recent dividends of $0.03 per share were distributed in April, May, and June 2026, reflecting a stable income component. Key support lies at $56, with resistance near $57.
Outlook remains balanced; dividend consistency supports income investors, but limited fundamental data and neutral technicals suggest cautious optimism. Risks include market volatility and reliance on broader dividend strategy performance. Upside depends on sustained dividend growth and favorable market conditions for income-focused equities.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
